Hematology
Blood & lymphatic clinical trials
Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We’re tracking 4,918 recruiting studies in this area right now.
By phase
- Not applicable2,022
- Phase 21,072
- Phase 1792
- Phase 1/Phase 2478
- Phase 3345
- Phase 4126
- Phase 2/Phase 383
Top conditions
- Multiple Myeloma327
- Acute Myeloid Leukemia281
- Lymphoma178
- Sickle Cell Disease134
- Myelodysplastic Syndromes128
- Acute Lymphoblastic Leukemia118
- Leukemia100
- Chronic Lymphocytic Leukemia95
- Follicular Lymphoma70
- Hematologic Malignancy67
- Myelodysplastic Syndrome64
- Hodgkin Lymphoma63
- Mantle Cell Lymphoma62
- Anemia56
- Diffuse Large B Cell Lymphoma54
- Malignant Solid Neoplasm53
- Acute Myeloid Leukemia (AML)48
- Lymphedema48
Leading sponsors
- M.D. Anderson Cancer Center145
- Institute of Hematology & Blood Diseases Hospital, China138
- National Cancer Institute (NCI)96
- The First Affiliated Hospital of Soochow University67
- Memorial Sloan Kettering Cancer Center63
- City of Hope Medical Center58
- Mayo Clinic55
- Assistance Publique - Hôpitaux de Paris45
- St. Jude Children's Research Hospital44
- Peking University People's Hospital43
Where studies are running
- California396
- Texas185
- Alabama156
- Maryland152
- Arizona125
- Florida105
- Massachusetts103
- New York98
- Ohio70
- Minnesota69
Recruiting studies4,918 total
- NCT05338931RecruitingPhase 1/Phase 2
AT101 for relapsed or refractory B-cell lymphoma patients
This trial studies AT101 to see how safe it is, what side effects it causes, and whether it can help people with B-cell non-Hodgkin lymphoma that has come back or did not respond to treatment. It may be an option if your usual treatments are no longer working or aren’t suitable for you.
SeoulAges 19 years+ - NCT05431257RecruitingPhase 2
Azacitidine plus venetoclax for older or unfit AML
This Phase 2 study tests whether the combination of azacitidine and venetoclax can help people with acute myeloid leukemia (AML) who can’t handle standard intensive chemotherapy, including some relapsed or refractory cases. It also involves extra optional-style lab testing on your leukemia (bio-banking and “-omics” profiling) to learn which drug sensitivities may matter.
CopenhagenAges 18 years+ - NCT05436587Recruiting
Genetic testing study for hard-to-classify bone marrow failure
This study looks for gene changes in families affected by rare inherited bone marrow failure that can cause fragile bones and fractures. It may help doctors understand the condition better by linking genetic mutations with family health patterns.
SohagAges Any age - NCT05445154RecruitingPhase 1/Phase 2
New treatment for newly diagnosed FLT3 AML with oral drugs
This Phase 1/2 study tests SKLB1028 (with daunorubicin and cytarabine) in people with newly diagnosed acute myeloid leukemia (AML) who have an FLT3 mutation. It aims to see how well and how safely this treatment works for this specific type of AML.
ChengduAges 18–59 - NCT05445011RecruitingPhase 1
FLT3-targeted CAR-T for relapsed or resistant AML
This trial tests an engineered immune cell treatment (CAR-T) made to target FLT3, for adults with acute myeloid leukemia (AML) that has come back or did not respond to standard treatment. It aims to control the leukemia when options have been limited.
Wuhan, HubeiAges 18–70 - NCT05023564Recruiting
Dementia care study following people with a steady caregiver
This study follows people diagnosed with dementia over time, with the help of a consistent caregiver, to better understand how dementia changes. It may help by adding new information that could improve future care and planning for families.
BeijingAges 18 years+ - NCT04502394RecruitingPhase 1/Phase 2
Investigational drug combo for relapsed blood cancer
This trial combines two investigational drugs to see if they are safe and effective for patients with two types of blood cancer: diffuse large B-cell lymphoma (DLBCL) or chronic lymphocytic leukemia (CLL) that has come back or stopped responding to standard treatments. It may offer a new option when other treatments have not worked.
Goshen, IndianaAges 18 years+ - NCT02859402RecruitingPhase 2
Donor stem cell transplant for relapsed T or NK lymphoma
This Phase 2 study tests an allogeneic (donor) stem cell transplant for people with T-cell or NK-cell lymphomas that came back or did not respond to prior treatment. It may help by giving you new, healthy immune cells that can attack the cancer.
BusanAges 19–65 - NCT05506332RecruitingPhase 1
Venetoclax plus leukemia drugs for AML after treatment failure
This Phase 1 trial studies whether a combination of venetoclax (ABT-199) and “purine analogues” can help adults with AML that has come back or didn’t respond to earlier treatment. It’s designed to test safety and early effectiveness in people who haven’t previously developed resistance to venetoclax.
Edegem, AntwerpAges 18 years+ - NCT05506410Recruiting
Newly diagnosed mantle cell lymphoma study with Hanlikang and BTK drugs
This trial studies how well Hanlikang and a BTK inhibitor work for people newly diagnosed with mantle cell lymphoma. The goal is to improve lymphoma control while checking safety, since you must meet specific blood, organ, and health requirements.
Zhengzhou, HenanAges 18–90 - NCT05404906RecruitingPhase 2/Phase 3
Azacytidine plus venetoclax to prevent AML coming back
This trial studies azacytidine (AZA) plus venetoclax as maintenance treatment to help keep acute myeloid leukemia (AML) in first remission. It may help delay or prevent AML from returning in younger adults who cannot get a stem cell transplant right away.
Suzhou, JiangsuAges 18–64 - NCT05518383RecruitingPhase 4
Pediatric B-cell lymphoma treatment study using established care
This trial studies treatment for children and teens with certain B-cell non-Hodgkin lymphomas using a specific treatment protocol. It may help doctors confirm how well the regimen works in young patients and improve care over time.
Moscow, RFAges 1 day–18 years - NCT04442412RecruitingPhase 3
Prednisone and vitamin D before chemo for certain lymphomas
This Phase 3 study tests whether a short “pre-treatment” with prednisone, with or without vitamin D, can improve outcomes when followed by standard lymphoma chemo. It aims to see if adding vitamin D early can help older adults tolerate or benefit from treatment for specific lymphoma types.
Brescia, BSAges 65 years+ - NCT05528055RecruitingPhase 1
Safety study of SCR-6920 for advanced cancers
This Phase 1 trial tests whether SCR-6920 capsules are safe and tolerable in people with advanced, treatment-resistant cancers. It may help doctors learn the right way to dose the medicine and check for side effects.
Jinan, ShandongAges 18–75 - NCT05521204RecruitingPhase 2
Olverembatinib for cancers with FGFR1 gene changes
This trial studies olverembatinib to treat certain blood cancers that have an FGFR1 rearrangement (a specific gene change). It’s for people whose disease is newly diagnosed, has progressed, or has come back, and who can safely take the study medicine and attend follow-up visits.
Suzhou, JiangsuAges Any age - NCT02852928Recruiting
ChILD-EU registry for childhood lung disease samples
This trial builds a European “registry and biobank” of children with suspected or confirmed interstitial lung disease (a type of lung problem), as well as conditions that can look similar. It helps researchers learn more about these rare childhood lung diseases and connect families to future studies.
Hanover, Lower SaxonyAges Any age - NCT05584761RecruitingPhase 1/Phase 2
Cord blood stem cells plus azacitidine for advanced blood cancers
This trial tests whether adding donated cord blood stem cells to azacitidine can improve outcomes for people with advanced MDS, CMML-2, or a certain type of AML. It may help by giving the treatment a stronger chance to control abnormal blood-forming cells.
Nanjing, JiangsuAges 18–80 - NCT02714387Recruiting
Study of serious complications from non-traumatic blood vessel brain problems
This study follows people who have non-injury (non-traumatic) blood-vessel-related problems in the brain to understand serious complications. It may help researchers identify risks and improve care over time.
AngersAges 15 years+ - NCT04689750Recruiting
Testing outcomes after donor CHIP in stem cell transplant
This study looks at how a genetic risk factor in a stem cell donor (called CHIP) may affect outcomes after an allogeneic (donor-to-recipient) stem cell transplant. It may help doctors better predict which donor factors are important for patient outcomes.
Hong KongAges 18 years+ - NCT03852407RecruitingPhase 2
Two kinds of conditioning before matched stem cell transplant
This trial compares two reduced-intensity conditioning regimens before you receive stem cells from a donor who matches your HLA type. It aims to find which approach works better and is safer for certain blood cancers.
AntwerpAges 18–75 - NCT05571774Recruiting
Building a database for severe ADAMTS13 deficiency
This trial is creating a research database for people with severe ADAMTS13 deficiency, a condition where the body has very low activity of a key blood-protein. It may help researchers better understand the condition by collecting and organizing patient information.
Suzhou, JiangsuAges Any age - NCT04922567RecruitingPhase 2
Lenalidomide plus CHOP versus CHOP for untreated PTCL
This Phase 2 trial compares two chemotherapy approaches—adding lenalidomide to CHOP versus CHOP alone—for people with untreated peripheral T-cell lymphoma (PTCL). The goal is to see if the added medicine improves response and safety.
Hangzhou, ZhejiangAges 18–75 - NCT03848962Recruiting
Share leftover or collected samples for research
This study helps collect and share human samples (like blood or other specimens) so researchers can do new studies. It’s mainly about providing samples for research use, not testing a treatment on you.
Huntsville, AlabamaAges 1 month–89 years - NCT05626400Recruiting
CAR T for relapsed T-ALL or T-LBL with CD7
This trial tests a type of immune therapy (CAR T cells) called Senl-T7 in people whose T-cell leukemia or lymphoma has come back or did not respond. It aims to target cancer cells that carry a marker called CD7.
Beijingcun, HebeiAges 2–70
Common questions
- How many blood & lymphatic clinical trials are recruiting?
- Clin2 is tracking 4,918 recruiting hematology studies from the U.S. registry right now, out of 7,266 we cover in this area in total.
- What does “Blood & lymphatic” cover here?
- Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We group each study into blood & lymphatic based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a blood & lymphatic trial near me?
- Use the search to filter blood & lymphatic studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.